Session: 908. Outcomes Research: Myeloid Malignancies: Poster I
Hematology Disease Topics & Pathways:
Diversity, Equity, and Inclusion (DEI), Diseases, Lymphoid Malignancies, Myeloid Malignancies
Methods:
We conducted a retrospective review of patients with hematologic malignancies referred to the Center for Immuno-Oncology (CIO)-HCT team at the NIH between 1/1/2020-12/31/2022, with review of post-referral outcomes through 12/31/2023. Data was analyzed descriptively using GraphPad Prism v10. This study included review of patients referred for IRB-approved clinical trials NCT04959175, NCT03983850, NCT05327023, NCT05436418, NCT03922724, NCT05470491.
Results:
331 patients were referred to the CIO-HCT team during the 3-year study period, with 87 (26%) reaching HCT at NIH. Of these 331 patients, 240 (72%) were sufficiently engaged in the referral process to be assigned a medical record number (MRN). Of the 91 that did not get an MRN, 40% were referred in 2020, 36% in 2021, and 24% in 2022. Of the 240 patients that obtained an MRN (MRN-referrals) 148 were male and 92 were female, with comparable HCT rates (35% vs. 37%, respectively). Of MRN-referrals with known marital status, 110 were married and 36% underwent HCT; 96 identified as single/divorced and 46% underwent HCT. Among the MRN-referrals, 53% were Hispanic, 24% were non-Hispanic White, and 14% were Black. 41% of Black patients underwent HCT, compared to 39% Hispanics and 30% non-Hispanic White patients. 55% of MRN-referrals that underwent HCT were non-English speaking. Median age of patients who underwent HCT was 44 years (range 13-71 years); 41% were <40 years.
Median time from referral to HCT was 137 days (range 32-1377 days). Time from referral to HCT was significantly longer for non-English speaking patients (191 days vs. 116 days; p=0.0014) and single/divorced patients (163 days vs. 127 days; p=0.04).
Median income by zip code for all patients who received HCT and lived in the U.S. (N=78) was $89,797. Single/divorced patients who received HCT lived in areas with significantly lower zip code median income compared to married patients who received HCT ($83,261 vs. $104,091; P=0.03) and patients <40 years who received HCT also lived in areas with significantly lower median income compared to those >40 years of age ($83,360 vs. $101,374; p= 0.03).
Median ADI for all transplanted patients was 38 (range 1-99). ADI was significantly higher for male vs. females (47 vs. 23; p=0.02), single/divorced vs. married (51 vs. 20; p=0.002), non-English-speaking patients vs. English-speaking patients (46 vs. 24; p=0.03), and patients aged <40 years vs. > 40 years (53 vs. 24.5, p=0.015). There were no ADI differences by race/ethnicity.
Median distance from home address to the NIH was 283 miles; there was no significant differences in median distance travelled across groups.
Conclusion:
Without health insurance as a requisite, 26% of referred patients successfully underwent HCT during the study period. There was a higher early disengagement rate in 2020, perhaps due to the SARS CoV-2 pandemic. Successful referrals did not differ by race/ethnicity, sex, or marital status, but time from referral to HCT was significantly longer for patients whose language was not English and for single/divorced patients. Transplanted patients who were male, non-English speaking, single/divorced, and <40 years of age had lower socioeconomic status, but these factors did not affect the successful receipt of HCT. Therefore, when insurance is not a barrier, high rates of underrepresented minorities and non-English speaking patients can successfully reach HCT, although delays exist. Future work will delve further into socio-demographic differences in HCT access.
Disclosures: No relevant conflicts of interest to declare.
See more of: Oral and Poster Abstracts